Tenon Medical Regains Compliance with Nasdaq Minimum Bid Price RequirementLOS GATOS, CA / ACCESS Newswire / August 24, 2026 / Tenon Medical, Inc. (
NASDAQ:TNON) ("Tenon" or the "Company"), a medical device company dedicated to transforming care for patients with certain sacro-pelvic disorders, today announced that it has received notice from The Nasdaq Stock Market LLC ("Nasdaq") confirming that the Company has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the "Bid Price Rule").
Tenon Medical Reports Second Quarter 2026 Financial Results~ Second Quarter 2026 Revenue of $1.3 Million, a 127% Increase Compared to Prior Year ~
Tenon Medical, Inc. Announces 1:35 Reverse Stock SplitLOS GATOS, CA / ACCESS Newswire / August 6, 2026 / Tenon Medical, Inc. (
NASDAQ:TNON) ("Tenon" or the "Company"), a medical device company dedicated to transforming care for patients with certain sacro-pelvic disorders, today announced a 1-for-35 reverse stock split of the Company's issued and outstanding common stock.
Tenon Medical, Inc. Sets Date for Second Quarter 2026 EarningsLOS GATOS, CA / ACCESS Newswire / July 30, 2026 / Tenon Medical, Inc. (
NASDAQ:TNON)("Tenon" or the "Company"), a medical device company dedicated to transforming care for patients with certain sacro-pelvic disorders, today announced plans to release financial results for the second quarter ended June 30, 2026 after market close on Thursday, August 13, 2026. The Company will also hold a conference call on the same day at 4:30 p.m. Eastern Time to discuss its financial results in further detail. The call will conclude with a Q&A session with its covering analysts.
Tenon Medical, Inc. Announces Regained Compliance with Nasdaq Stockholders' Equity RequirementLOS GATOS, CA / ACCESS Newswire / July 20, 2026 / Tenon Medical, Inc. (
NASDAQ:TNON) ("Tenon" or the "Company"), a medical device company dedicated to transforming care for patients with certain sacro-pelvic disorders, today announced that it has received notice from Nasdaq that the Company regained compliance with the continued listing requirement relating to maintaining a minimum of $2.5 million in stockholders' equity.
Tenon Medical(R) Announces FDA 510(k) Clearance for Catamaran(R) SI Joint Fusion System~ Updated clearance incorporates various instrument upgrades, as well as per-procedure costs, improving unit economics driven by the reclassification of certain instruments from disposable to reusable status ~
Tenon Medical, Inc. Announces Closing of $4.2 Million Public OfferingLOS GATOS, CA / ACCESS Newswire / July 1, 2026 / Tenon Medical, Inc. (
NASDAQ:TNON) ("Tenon" or the "Company"), a medical device company dedicated to transforming care for patients with certain sacro-pelvic disorders, announced that it has closed its previously announced public offering of securities as described below for aggregate gross proceeds to the Company of $4.2 million, before deducting placement agent fees and other estimated offering expenses payable by the Company.
Tenon Medical, Inc. Announces Pricing of $4.2 Million Public OfferingLOS GATOS, CA / ACCESS Newswire / June 30, 2026 / Tenon Medical, Inc. (
NASDAQ:TNON) ("Tenon" or the "Company"), a medical device company dedicated to transforming care for patients with certain sacro-pelvic disorders, announced that it has priced a public offering of securities as described below for aggregate gross proceeds to the Company of approximately $4.2 million, before deducting placement agent fees and other estimated offering expenses payable by the Company.
Tenon Medical, Inc. Announces Timing of Second Quarter 2022 Financial ResultsLOS GATOS, CA / ACCESSWIRE / July 27, 2022 / Tenon Medical, Inc. ("Tenon" or the "Company"), a medical device company that has developed a proprietary, U.S. Food and Drug Administration ("FDA") cleared surgical implant system for sacroiliac joint ("SI Joint") fixation/fusion surgery, today announced plans to release financial results for the second quarter ended June 30, 2022 after market close on Thursday, August 11, 2022. The Company will also hold a conference call the same day at 4:30 p.m. Eastern Time to discuss its financial results in further detail. The call with conclude with a Q&A session.
Tenon Medical, Inc. Announces the Posting of New Corporate Presentation via the Investor Relations WebsiteLOS GATOS, CA / ACCESSWIRE / May 31, 2022 / Tenon Medical, Inc. ("Tenon" or the "Company"), a medical device company that has developed a proprietary, U.S. Food and Drug Administration ("FDA") cleared surgical implant system for sacroiliac joint ("SI Joint") fixation/fusion surgery, today announced the Company has posted its new corporate presentation accessible via the Company's Investor Relations website at http://ir.tenonmed.com/.
Tenon Medical, Inc. Announces Upcoming Virtual Conference ParticipationLOS GATOS, CA / ACCESSWIRE / May 25, 2022 / Tenon Medical, Inc. ("Tenon" or the "Company"), a medical device company that has developed a proprietary, U.S. Food and Drug Administration ("FDA") cleared surgical implant system for sacroiliac joint ("SI Joint") fixation/fusion surgery, today announced the Company will participate in The Benchmark Company Healthcare House Call Virtual 1x1 Investor Conference on Thursday, June 2, 2022.
Tenon Medical, Inc. Announces Closing of $16,000,000 Initial Public OfferingOur newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence.
Tenon Medical, Inc. Announces Pricing of $16 Million Initial Public OfferingLOS GATOS, CA / ACCESSWIRE / April 26, 2022 / Tenon Medical, Inc. ("Tenon" or the "Company"), a medical device company that has developed a proprietary, U.S. Food and Drug Administration ("FDA") cleared surgical implant system for sacroiliac joint ("SI Joint") fixation/fusion surgery, today announced the pricing of its initial public offering of 3,200,000 shares of its common stock at a price of $5.00 per share which reflects a 2 for 1 reverse
